# A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

> **NCT03733561** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** LY03003
- **DRUG:** Neupro 4Mg/24Hr Transdermal Patch

## Key facts

- **NCT ID:** NCT03733561
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2018-12-23
- **Final completion:** 2018-12-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733561, "A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03733561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*